BTK Inhibitors in Chronic Lymphocytic Leukemia
Brad S. Kahl, MD, explores the most recent data surrounding the use of Bruton tyrosine kinase inhibitors acalabrutinib and zanubrutinib in chronic lymphocytic leukemia.
Related Articles
Sunvozertinib Receives Breakthrough Therapy Designation for Treatment-Naive EGFR Exon 20+ NSCLC in China
China’s CDE has granted breakthrough therapy designation to first-line sunvozertinib for EGFR exon 20 insertion mutation–positive NSCLC.
Chemoimmunotherapy Is at the Forefront of the Perioperative NSCLC Paradigm
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Empowering Breast Surgeons: A Call for Collective Action
As survival rates continue to rise for patients with breast cancer, innovations are still needed to advance surgical care for these patients.
Meta-Analysis Shows Efficacy, Safety of CAR T-Cell Therapy in R/R Mantle Cell Lymphoma
CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.
Integration of Lutetium Lu 177 Vipivotide Tetraxetan Highlights Potential of Radioligands in Prostate Cancer
Daniel J. George, MD, discusses ongoing research aimed at improving outcomes for prostate cancer patients in recognition of Prostate Cancer Awareness Month.
Belantamab Mafodotin Plus KRd Is Effective With Manageable Toxicities in R/R Multiple Myeloma
Belantamab mafodotin plus KRd was associated with a manageable safety profile and deep responses in pretreated patients with multiple myeloma.
Prostate Cancer Awareness Efforts Target Patient Education, Treatment Access, and Survivorship Care
Bertram Yuh, MD, discusses the value of genetic testing, long-term disease management, and raising awareness during Prostate Cancer Awareness Month.
First-Line Cadonilimab Plus Chemo Wins Approval in China for Advanced Gastric/GEJ Adenocarcinoma
Cadonilimab plus chemotherapy has been approved in China for first-line locally advanced or metastatic gastric/GEJ adenocarcinoma.
Bosutinib Yields Long-Term Efficacy and Safety in TKI-Pretreated CML
Treatment with bosutinib led to high response rates with a manageable safety profile in patients with CML who had previously received a TKI.
FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma
Dr Taylor discusses the significance of the FDA approval of vorasidenib for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma.